Skip to content
Head to head

Replimune vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: REPL · VRTX

Updated 3 minutes ago

1-year performance, rebased to 100

REPL +117.4%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
REPLVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price19.07515.02
Change today-0.83%-1.08%
1-year return+111.7%+22.0%
Market cap$1.81B$130.58B
52-week range1.50 – 23.54412.27 – 568.67
Valuation
P/E (TTM)-6.8433.14
P/E percentile, own 5-yr range17th99th
P/B8.836.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-3.3815.32
Net profit (TTM)$-320.43M$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-245.77M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership107.7%96.8%
Insider activity (12mo)27 buy / 23 sell28 buy / 22 sell
Short interest (% of float)26.0%1.9%
Analyst consensus100% buy (5)95% buy / 5% hold (21)
Analyst price target$24 (+26%)$624 (+21%)
StockVane view
StockVane Quant RatingC (98)C (68)
Company
Employees4656,400
Founded20171989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.